Back to BAX Stock Lookup

Baxter (BAX) – Press Releases

Apr 27, 2015 09:00 PM PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission to U.S. FDA
Apr 27, 2015 07:00 AM Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 23, 2015 07:00 AM Baxter Reports First Quarter Financial Results That Exceed Guidance
Apr 22, 2015 01:30 AM CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
Apr 21, 2015 04:15 PM Baxter to Webcast Annual Meeting of Shareholders
Apr 21, 2015 09:00 AM Baxter Supports IPOPI Initiative to Improve Global Care of Primary Immunodeficiencies During 5th Annual World PI Week
Apr 17, 2015 04:30 PM Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease
Apr 16, 2015 09:00 AM Baxter Submits Application to Japan’s MHLW for Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A
Apr 15, 2015 08:00 AM Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement
Apr 7, 2015 04:15 PM Baxter International First Quarter 2015 Financial Results Conference Call
Apr 2, 2015 08:00 AM Baxter and Laboratoire Aguettant Announce Global Collaboration for Parenteral Nutrition Trace Elements
Apr 1, 2015 08:00 AM Baxter Completes CE Mark Approval for HOMECHOICE CLARIA Automated Peritoneal Dialysis System with SHARESOURCE
Mar 30, 2015 09:00 AM Baxter Expands Access to Healthcare Through Collaborations and Charitable Giving
Mar 20, 2015 03:46 PM Fitch Maintains Baxter International on Rating Watch Negative
Mar 13, 2015 09:00 AM Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant Treatment for Hemophila A and B Patients with Inhibitors
Mar 9, 2015 07:00 AM CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis
Mar 4, 2015 09:00 AM Baxter’s BioScience Business Acquires Biopharmaceutical Company SuppreMol
Feb 23, 2015 09:00 AM Baxter Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters
Feb 19, 2015 04:15 PM Baxter to Present at Barclay’s Global Healthcare Conference
Feb 17, 2015 09:00 AM Baxter Declares Quarterly Dividend
Feb 12, 2015 04:30 PM Baxter Provides Progress Update on Gene Therapy Program, Including Phase I/II Clinical Trial of BAX 335, Investigational Gene Therapy Treatment for Hemophilia B
Feb 11, 2015 09:00 AM Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Feb 10, 2015 04:15 PM Baxter to Present at Cowen & Company’s 35th Annual Health Care Conference
Jan 29, 2015 07:00 AM Baxter’s Fourth Quarter Financial Results Exceed Expectations

Back to BAX Stock Lookup